

Breakfast with the Investigators: Current and Emerging Role of Antibody-Drug Conjugates in the Treatment of Lung Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. According to data from the Phase III TROPION-Lung01 trial, datopotamab deruxtecan (Dato-DXd) appears to be more efficacious in patients with which type of previously treated advanced non-small cell lung cancer (NSCLC)?
 - a. Squamous
 - b. Nonsquamous**
 - c. Neither of the above — patients with either histology benefitted equally
2. Telisotuzumab vedotin is directed against which of the following proteins?
 - a. HER2
 - b. c-Met**
 - c. TROP2
 - d. VEGF
3. Ifinatamab deruxtecan targets which of the following proteins?
 - a. HER2
 - b. HER3
 - c. TROP2
 - d. B7-H3**
4. Which of the following statements best describes observations with lower-dose (5.4 mg/kg) versus higher-dose (6.4 mg/kg) trastuzumab deruxtecan in the Phase II DESTINY-Lung02 trial for patients with NSCLC with HER2 mutations?
 - a. The lower dose was more tolerable but less efficacious
 - b. The 2 doses were similar in tolerability and efficacy
 - c. The lower dose was more tolerable and similarly efficacious**
5. Which of the following statements best describes progression-free survival outcomes with Dato-DXd in the intention-to-treat population of patients with previously treated NSCLC in the Phase III TROPION-Lung01 trial?
 - a. Dato-DXd was inferior to docetaxel
 - b. Dato-DXd was noninferior to docetaxel
 - c. Dato-DXd was superior to docetaxel**